Stine Rasmussen Meehan, PhD

Patient-Reported Effects of Adjunctive Brexpiprazole on Calming and Engagement in Major Depressive Disorder: Post Hoc Analysis of Clinical Trial Exit Interviews

Background: Calming patients (without sedation) and increasing engagement (without overactivation) are important components of the successful treatment of major depressive disorder (MDD)....

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Catherine Gupta , PhD;

Michael Thase , MD;

Zahinoor Ismail , MD;

Roger McIntyre , MD, FRCPC;

T. Michelle Brown , PhD;

10/08/2020

Efficacy and Safety of Brexpiprazole in Patients With Schizophrenia Presenting With Severe Psychotic Symptoms During an Acute Exacerbation

Background: Schizophrenia is a chronic, disabling and progressive disease, with heterogenous symptoms and disease course between individuals. Severity of symptoms has been shown to be a s...

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Nicole Meade , PhD;

Lily Shi , MSc;

03/01/2019

Examining Depressive Symptoms Across Diagnostic and Statistical Manual Indications: Treatment Effects of Brexpiprazole in Patients With Major Depressive Disorder and Schizophrenia

Background: The NIMH Research Domain Criteria (RDoC) framework could be used to recategorize symptoms across the established DSM criteria for neuropsychiatric disorder indications. This p...

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Malaak Brubaker , PhD;

Dalei Chen , PhD;

Ross Baker , PhD, MBA;

Ruth Duffy , PhD;

10/08/2020

Efficacy of Adjunctive Brexpiprazole in Adults With MDD: Improvement of Patient Engagement Based on Selected Items From the Inventory of Depressive Symptomatology Self-Report (IDS-SR) Scale

Objective: These post-hoc analyses used relevant items from the IDS-SR to explore whether treatment with adjunctive brexpiprazole in patients with MDD has potential to improve a new conce...

Anne Pedersen , MSc;

Klaus Groes Larsen , PhD;

Anna-Greta Nylander , PhD;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Michael Thase , MD;

Zahinoor Ismail , MD;

Dalei Chen , PhD;

Ross Baker , PhD, MBA;

Roger McIntyre , MD, FRCPC;

11/22/2019

Effect of Adjunctive Brexpiprazole on Sexual Functioning in MDD According to Concomitant Antidepressant: Post Hoc Analysis of Four Short-Term Studies

Background: We aimed to determine the effects of adjunctive brexpiprazole on sexual functioning in adults with major depressive disorder (MDD), according to antidepressant treatment (ADT)...

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

Malaak Brubaker , PhD;

Peter Zhang , PhD;

Mary Hobart , PhD;

11/22/2019

The Impact of Second-Generation Antipsychotic Side-Effects on Functioning From a Schizophrenia Patient Perspective: A Global Patient Centered Survey

Background: The impact of side effects (SEs) of second-generation antipsychotics (SGAs) on patients’ physical and emotional functioning and overall quality of life (QoL) is insufficiently...

Mallik Greene , PhD, DBA;

Laetitia Bouerat Duvold , PhD;

Catherine Weiss , PhD;

William Lenderking , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

Huda Shalhoub , PhD;

Carla Dias-Barbosa , MSc;

Jun Chen , MS, MSc;

Andrea Schulz , MA;

Ann Hartry , PhD;

11/22/2019

Short- and Long-Term Metabolic Changes in Patients with MDD Treated with Adjunctive Brexpiprazole or Adjunctive Aripiprazole: An Indirect Comparison

Objective: We aimed to describe metabolic changes observed during short- and long-term studies of brexpiprazole and aripiprazole in patients with MDD.

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Peter Zhang , PhD;

Erin MacKenzie , PhD;

Francois Therrien , PharmD;

Ross Baker , PhD, MBA;

11/22/2019

Efficacy of Adjunctive Brexpiprazole in Major Depressive Disorder: A Pooled Response Quartile Analysis

Background: We assessed varying levels of response to brexpiprazole adjunctive to standard antidepressant therapy (ADT).

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Mary Hobart , PhD;

Dalei Chen , PhD;

11/22/2019

Predictors of Weight Change After Long-Term Treatment With Brexpiprazole in Schizophrenia

Background: We assessed effects contributing to weight gain during long-term treatment with brexpiprazole.

Mette Josiassen , PhD;

Anders Tvistholm , MS;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Mary Hobart , PhD;

Ross Baker , PhD, MBA;

11/22/2019

Exploring Patient Experiences Taking Adjunctive Brexpiprazole for Major Depressive Disorder (MDD): Post-hoc Analysis of Exit Interview Data

Background: The efficacy and safety of adjunctive brexpiprazole, a serotonin–dopamine activity modulator, has been demonstrated in clinical studies in adults with MDD and inadequate respo...

Michelle Brown , PhD;

Catherine Gupta , PhD;

Dana DiBenedetti , PhD;

Michael Thase , MD;

Zahinoor Ismail , MD;

Roger McIntyre , MD, FRCPC;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

11/22/2019